Stopping this DMT during pregnancy increases relapse-related disability risk

Published: 08 February 2022

People with multiple sclerosis (MS) who stop taking Tysabri (natalizumab) during pregnancy have a significant risk of relapse-related disability, a new study has found. 

Researchers analysed data of 255 pregnant women from the German Multiple Sclerosis and Pregnancy Registry who stopped taking Tsabri. A year after the births of their babies, almost 11% had significant relapse-related disability. There were also commonly relapses during pregnancy and in the postpartum period – 183 women relapsed during pregnancy, with 44 women experiencing a severe relapse. One year postpartum, 29 women had significant relapse-related disability accumulated from their pregnancy. 

The researchers said although the full implications of treatment with Tysabri before pregnancy are still unclear, the results may help inform a risk-benefit discussion between women taking Tysabri who are planning a pregnancy and their neurologist.